OncLive TV

Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.

Lionel A. Kankeu Fonkoua, MD, discusses how the platinum chemotherapy shortage in the United States may exacerbate disparities in cancer care and the importance of conducting research to investigate the potential implications of this shortage on patients in underserved communities.

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.

Zachery Roger Reichert, MD, PhD, discusses novel agents and pathways under exploration in prostate cancer.

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

Ahmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.

Brian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma.

Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

Carolina D. Schinke, MD, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Isabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.

Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Isabelle Franklin, discusses future steps to be taken following an investigation into the association between self-reported social needs and colorectal cancer screening rates.

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

Joshi Alumkal, MD, discusses the effects of the phase 3 ARESENS trial on the treatment of metastatic hormone-sensitive prostate cancer.

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Angel Qin, MD, discusses her process when choosing between targetable agents for patients with EGFR exon 20–mutated lung cancer.

Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.